Stoke Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Stoke Therapeutics, Inc. (STOK) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 13.69 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-03
- Stoke Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 13.69M shares, a 18.63% increase year-over-year.
- Stoke Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 13.31M shares, a 68.97% increase year-over-year.
- Stoke Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 11.34M shares, a 2.88% increase year-over-year.
- Stoke Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 11.54M shares, a 10.38% increase year-over-year.
- Stoke Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 12.12M shares, a 28.49% increase from fiscal 2024.
- Stoke Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 9.44M shares, a 18.08% increase from fiscal 2023.
- Stoke Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 7.99M shares, a 3.43% decline from fiscal 2022.
- Stoke Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 8.27M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 13.69M shares 10-Q · filed 2026-08-03 | 13.69M shares 10-Q · filed 2026-08-03 | ||
| 2026-03-31 | 13.31M shares 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 12.12M shares 10-K · filed 2026-03-16 | |||
| 2025-09-30 | 11.34M shares 10-Q · filed 2025-11-04 | 6.88M shares 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | 11.54M shares 10-Q · filed 2026-08-03 | 7.95M shares 10-Q · filed 2026-08-03 | ||
| 2025-03-31 | 7.88M shares 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 9.44M shares 10-K · filed 2026-03-16 | |||
| 2024-09-30 | 11.03M shares 10-Q · filed 2025-11-04 | 11.03M shares 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | 10.46M shares 10-Q · filed 2025-08-12 | 10.46M shares 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | 9.85M shares 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | 7.99M shares 10-K · filed 2025-03-18 | |||
| 2023-09-30 | 10.25M shares 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | 10.23M shares 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | 10.05M shares 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | 8.27M shares 10-K · filed 2024-03-25 | |||
| 2021-03-31 | 5.38M shares 10-Q · filed 2021-05-10 | |||
| 2020-09-30 | 4.89M shares 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | 4.86M shares 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | 4.99M shares 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | 4.24M shares 10-K · filed 2020-03-23 | |||
| 2019-09-30 | 4.22M shares 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | 4.19M shares 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | 26.71M shares 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | 26.16M shares 10-K · filed 2020-03-23 | |||
| 2018-09-30 | 14.72M shares 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | 11.13M shares 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |